Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

被引：2
|
作者：
Thomas, Xavier
Rijneveld, Anita W.
Fracchiolla, Nicola
Salek, Cyril
Spyridonidis, Alexandros
Chiaretti, Sabina
Alam, Naufil
Grueter, Isabella Pezzani
Mohammad, Abeera
Kormany, William
Kreuzbauer, Georg
Rambaldi, Alessandro
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134470
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study
    Short, Nicholas J.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Huang, Xuelin
    Ferrajoli, Alessandra
    Kadia, Tapan M.
    Thompson, Philip A.
    Alvarado, Yesid
    Jain, Nitin
    Yilmaz, Musa
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Kornblau, Steven M.
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Schroeder, Heather M.
    Kwari, Monica
    Paul, Shilpa
    Nwakanme, Benjamin
    Loiselle, Christopher
    Garris, Rebecca
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [22] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
    Thomas E. Delea
    Xinke Zhang
    Jordan Amdahl
    Diana Boyko
    Franziska Dirnberger
    Marco Campioni
    Ze Cong
    PharmacoEconomics, 2019, 37 : 1177 - 1193
  • [23] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
    Delea, Thomas E.
    Zhang, Xinke
    Amdahl, Jordan
    Boyko, Diana
    Dirnberger, Franziska
    Campioni, Marco
    Cong, Ze
    PHARMACOECONOMICS, 2019, 37 (09) : 1177 - 1193
  • [24] Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
    Locatelli, Franco
    Whitlock, James A.
    Peters, Christina
    Chen-Santel, Christiane
    Chia, Victoria
    Dennis, Robyn M.
    Heym, Kenneth M.
    Katz, Aaron J.
    Kelsh, Michael A.
    Sposto, Richard
    Tu, Huakang
    Tuglus, Catherine A.
    Verma, Anupam
    Vinti, Luciana
    Wilkes, Jennifer J.
    Zubarovskaja, Nathalya
    Zugmaier, Gerhard
    von Stackelberg, Arend
    Sun, Weili
    LEUKEMIA, 2020, 34 (09) : 2473 - 2478
  • [25] Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
    Franco Locatelli
    James A. Whitlock
    Christina Peters
    Christiane Chen-Santel
    Victoria Chia
    Robyn M. Dennis
    Kenneth M. Heym
    Aaron J. Katz
    Michael A. Kelsh
    Richard Sposto
    Huakang Tu
    Catherine A. Tuglus
    Anupam Verma
    Luciana Vinti
    Jennifer J. Wilkes
    Nathalya Zubarovskaja
    Gerhard Zugmaier
    Arend von Stackelberg
    Weili Sun
    Leukemia, 2020, 34 : 2473 - 2478
  • [26] CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis
    Horst, Heinz-August
    Zugmaier, Gerhard
    Martinelli, Giovanni
    Mergen, Noemi
    Velasco, Kelly
    Zaman, Faraz
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (08) : E222 - E225
  • [27] Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)
    Critchlow, Simone
    Cooper, Miranda
    van Oostrum, Ilse
    Welch, Verna L.
    Russell-Smith, T. Alexander
    BLOOD, 2019, 134
  • [28] Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan
    Goto, Hideki
    Kitawaki, Toshio
    Fujii, Nobuharu
    Kato, Koji
    Onishi, Yasushi
    Fukuhara, Noriko
    Yamauchi, Takuji
    Toratani, Kazunori
    Kobayashi, Hiroki
    Yoshida, Shota
    Shimo, Masatoshi
    Onodera, Koichi
    Senjo, Hajime
    Onozawa, Masahiro
    Hirata, Kenji
    Yokota, Isao
    Teshima, Takanori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (06) : 816 - 826
  • [29] Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan
    Hideki Goto
    Toshio Kitawaki
    Nobuharu Fujii
    Koji Kato
    Yasushi Onishi
    Noriko Fukuhara
    Takuji Yamauchi
    Kazunori Toratani
    Hiroki Kobayashi
    Shota Yoshida
    Masatoshi Shimo
    Koichi Onodera
    Hajime Senjo
    Masahiro Onozawa
    Kenji Hirata
    Isao Yokota
    Takanori Teshima
    International Journal of Clinical Oncology, 2023, 28 : 816 - 826
  • [30] COST-EFFECTIVENESS OF BLINATUMOMAB VERSUS STANDARD OF CARE IN ADULT PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM A CANADIAN HEALTHCARE SECTOR PERSPECTIVE
    Delea, T. E.
    Raman, K.
    Boyko, D.
    Moynahan, A.
    Dirnberger, F.
    Despiegel, N.
    Tiwana, S.
    Sapra, S.
    VALUE IN HEALTH, 2020, 23 : S36 - S36
12345